Mirae Asset Global Investments Co. Ltd. Has $124.56 Million Stock Holdings in AbbVie Inc. $ABBV

Key Points

• Mirae Asset increased its AbbVie stake by 5.8% in the second quarter, adding 27,237 shares to hold 495,003 shares valued at approximately $124.6 million. Institutional investors and hedge funds collectively own 70.23% of AbbVie.
• Analyst sentiment remains favorable, with AbbVie carrying a “Moderate Buy” consensus rating and an average price target of $275.50; Wolfe Research upgraded the stock to “Outperform” with a $300 target.
• AbbVie reported strong quarterly results, including $3.65 in adjusted EPS and $16.99 billion in revenue, while neuroscience and post-Humira products support its growth outlook. However, the stock’s elevated valuation and pipeline setbacks present risks; it also pays a $1.73 quarterly dividend, yielding 2.8%.

Mirae Asset Global Investments Co. Ltd. increased its position in AbbVie Inc. (NYSE:ABBV - Free Report) by 5.8% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 495,003 shares of the company's stock after buying an additional 27,237 shares during the quarter. Mirae Asset Global Investments Co. Ltd.'s holdings in AbbVie were worth $124,563,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Litman Gregory Wealth Management LLC bought a new position in shares of AbbVie during the fourth quarter worth about $28,000. Imprint Wealth LLC increased its position in shares of AbbVie by 56.2% during the fourth quarter. Imprint Wealth LLC now owns 125 shares of the company's stock worth $29,000 after buying an additional 45 shares during the period. Legacy Wealth Managment LLC ID lifted its holdings in AbbVie by 115.9% in the fourth quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company's stock valued at $31,000 after buying an additional 73 shares during the period. IFC & Insurance Marketing Inc. acquired a new stake in AbbVie during the 4th quarter worth about $31,000. Finally, WestEnd Advisors LLC lifted its stake in shares of AbbVie by 160.4% in the 4th quarter. WestEnd Advisors LLC now owns 138 shares of the company's stock valued at $32,000 after purchasing an additional 85 shares during the period. 70.23% of the stock is currently owned by institutional investors and hedge funds.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Neuroscience growth is gaining momentum: AbbVie’s neuroscience franchise delivered strong first-half growth, with Parkinson’s treatment Vyalev accelerating. Potential approval and commercialization of tavapadon could provide another growth driver in the second half of 2026. Can ABBV's Neuroscience Drugs Drive Growth in the Second Half of 2026?
• Positive Sentiment: Post-Humira diversification remains a key bullish theme: Analysts and investors point to resilient revenue growth from AbbVie’s next-generation immunology and aesthetics portfolio. Wolfe Research upgraded AbbVie on pipeline strength and valuation, while BNP Paribas Exane also expects the stock to rise. Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation
• Positive Sentiment: Recent operating performance supports the growth case: AbbVie’s reported first-quarter 2026 revenue increased 12.4% year over year, while adjusted EPS exceeded internal expectations despite an acquired research-and-development charge. Could AbbVie Inc. Post-Humira Transformation Drive the Next Phase of Growth?
• Neutral Sentiment: Pipeline updates add potential but remain clinical-stage catalysts: AbbVie is expanding Alzheimer’s research with ABBV-1758 and studying Rinvoq against Humira in rheumatoid arthritis, while real-world China data for upadacitinib in atopic dermatitis could help reinforce Rinvoq’s commercial position. AbbVie Steps Deeper Into Alzheimer’s
• Negative Sentiment: Risks include valuation and pipeline uncertainty: A comparison with Bristol-Myers Squibb highlighted that AbbVie trades at a considerably richer valuation. Separately, the partners clarified a setback in the Phase 3 epcoritamab lymphoma study, and Erste Group Bank lowered its AbbVie earnings estimates—both potential sources of caution. Could AbbVie Win as Genmab Faces a New Regulatory Test for Epcoritamab?

Wall Street Analyst Weigh In

ABBV has been the subject of a number of research analyst reports. Wolfe Research upgraded AbbVie from a "peer perform" rating to an "outperform" rating and set a $300.00 target price for the company in a report on Thursday. JPMorgan Chase & Co. lifted their price objective on shares of AbbVie from $260.00 to $280.00 and gave the company an "overweight" rating in a report on Thursday, July 9th. Morgan Stanley reiterated an "overweight" rating and set a $296.00 price target on shares of AbbVie in a research note on Monday, August 3rd. Royal Bank Of Canada increased their price objective on AbbVie from $260.00 to $280.00 and gave the stock an "outperform" rating in a research note on Friday, July 10th. Finally, Canaccord Genuity Group increased their target price on shares of AbbVie from $282.00 to $290.00 and gave the company a "buy" rating in a report on Monday, August 3rd. Two analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $275.50.

AbbVie Trading Down 0.6%

AbbVie stock opened at $249.20 on Friday. AbbVie Inc. has a 1-year low of $190.75 and a 1-year high of $267.47. The firm has a market capitalization of $440.29 billion, a price-to-earnings ratio of 70.40, a P/E/G ratio of 0.83 and a beta of 0.30. The firm has a 50 day simple moving average of $244.94 and a 200 day simple moving average of $226.12.

AbbVie (NYSE:ABBV - Get Free Report) last issued its earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping the consensus estimate of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The business had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. During the same quarter last year, the company earned $2.97 EPS. The firm's revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, equities research analysts forecast that AbbVie Inc. will post 14.07 EPS for the current year.

AbbVie Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th were issued a $1.73 dividend. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $6.92 annualized dividend and a dividend yield of 2.8%. AbbVie's dividend payout ratio (DPR) is presently 195.48%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source